entertainment -WSS

entertainment

author：knowledge 2025-09-30 22:10:08 - browse：5311

Adam's take main illustration — Molly Ferguson/STAT

Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.

In other words, a lot like the content below. I’m really excited to get started and I hope you’ll find the newsletter worthy of your inbox real estate.

This week: A deep dive into the bull and bear sides of the Applied Therapeutics debate, and another well-deserved swipe at Cassava Sciences and its entirely ridiculous Alzheimer’s drug candidate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Plastic surgeons increase patient psychiatric screenings

WSS

Physicians and social media: If you see something, say something?

Diversifying clinical trials isn't enough to close racial gaps: study

Paying for Covid pills will soon shift to insurers

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Virtual Event: March of the Biosimilars

Creating egg and sperm cells from stem cells raises ethical issues

explore

entertainment

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Health AI adoption puts security, privacy startups on investors' radar

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Medical records are filled with copy

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Activists slam private health insurers over coverage restrictions

Readout Newsletter: New research from Sanofi, Regeneron, etc.

New air purifier tech could be key to improving indoor air quality

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Wikipedia

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Health AI adoption puts security, privacy startups on investors' radar

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Biden's order seeks to regulate AI risk without stifling innovation

SCOTUS questions limit to govt efforts to fight misinformation

WHO may add ‘noma' to its list of neglected tropical diseases

leisure time

explore

focus

explore